LIN C H, LIN S C, HUANG Y H, et al. Early Prediction of Olanzapine-Induced Weight Gain for Schizophrenia Patients[J]. Psychiatry Research, 2018, 263: 207-211. doi: 10.1016/j.psychres.2018.02.058
刘雪梅, 王伯初, 邓超, 等. 二代抗精神病药物介导脂代谢紊乱的机制研究进展[J]. 中国药学杂志, 2016, 51(3): 172-176.
SPERTUS J, HORVITZ-LENNON M, ABING H, et al. Risk of Weight Gain for Specific Antipsychotic Drugs: a Meta-Analysis[J]. Npj Schizophrenia, 2018, 4(1): 1794-1796.
SCHNEIDER M, PAUWELS P, TOTO S, et al. Severe Weight Gain as an Adverse Drug Reaction of Psychotropics: Data from the AMSP Project between 2001 and 2016[J]. European Neuropsychopharmacology, 2020, 36: 60-71. doi: 10.1016/j.euroneuro.2020.05.001
LIU X M, DENG C, CAO S, et al. Acute Effects of Oral Olanzapine Treatment on the Expression of Fatty Acid and Cholesterol Metabolism-Related Gene in Rats[J]. Life Sciences, 2015, 128: 72-78. doi: 10.1016/j.lfs.2015.01.033
ARJONA AA, ZHANG S X, ADAMSON B, et al. An Animal Model of Antipsychotic-Induced Weight Gain[J]. Behavioural Brain Research, 2004, 152(1): 121-127.
SHOBO M, YAMADA H, MIHARA T, et al. Two Models for Weight Gain and Hyperphagia as Side Effects of Atypical Antipsychotics in Male Rats: Validation with Olanzapine and Ziprasidone[J]. Behavioural Brain Research, 2011, 216(2): 561-568. doi: 10.1016/j.bbr.2010.08.046
SHAH R, SUBHAN F, ALI G, et al. Olanzapine Induced Biochemical and Histopathological Changes after Its Chronic Administration in Rats[J]. Saudi Pharm J, 2016, 24(6): 698-704. doi: 10.1016/j.jsps.2015.06.006
WESTON-GREEN K, HUANG X F, LIAN J M, et al. Effects of Olanzapine on Muscarinic M3 Receptor Binding Density in the Brain Relates to Weight Gain, Plasma Insulin and Metabolic Hormone Levels[J]. European Neuropsychopharmacology, 2012, 22(5): 364-373. doi: 10.1016/j.euroneuro.2011.09.003
WESTON-GREEN K, HUANG X F, DENG C. Olanzapine Treatment and Metabolic Dysfunction: a Dose Response Study in Female Sprague Dawley Rats[J]. Behavioural Brain Research, 2011, 217(2): 337-346. doi: 10.1016/j.bbr.2010.10.039
陈小英, 曾晏萍, 刘汉儒, 等. 太子参须多糖粗提物对小鼠免疫功能的调节作用[J]. 西南大学学报(自然科学版), 2020, 42(4): 56-64.
SCHLEIMER S B, JOHNSTON GA R, HENDERSON J M. Novel Oral Drug Administration in an Animal Model of Neuroleptic Therapy[J]. Journal of Neuroscience Methods, 2005, 146(2): 159-164. doi: 10.1016/j.jneumeth.2005.02.004
BALCOMBE J P, BARNARD N D, SANDUSKY C. Laboratory Routines Cause Animal Stress[J]. Contemporary Topics in Laboratory Animal Science, 2004, 43(6): 42-51.
李申. 抗精神病药引发体重和糖脂代谢改变的动态观察及相关基因关联性分析[D]. 天津: 天津医科大学, 2016.http://cdmd.cnki.com.cn/Article/CDMD-10062-1017874370.htm
曾晏萍, 胡钟艺, 陈小英, 等. 短期氟哌啶醇、利培酮、阿立哌唑作用对小鼠糖脂代谢及行为学影响[J]. 西南大学学报(自然科学版), 2019, 41(12): 40-49.
SHIMANO H, SATO R. SREBP-Regulated Lipid Metabolism: Convergent Physiology-Divergent Pathophysiology[J]. Nature Reviews Endocrinology, 2017, 13(12): 710-730. doi: 10.1038/nrendo.2017.91
兰英, 王继文, 曾兵, 等. 固醇调节元件结合蛋白-1c在肝脂肪合成中转录调节[J]. 安徽农业科学, 2005, 33(3): 499-501, 509. doi: 10.3969/j.issn.0517-6611.2005.03.082
WANG Y H, VISCARRA J, KIMS J, et al. Transcriptional Regulation of Hepatic Lipogenesis[J]. Nature Reviews Molecular Cell Biology, 2015, 16(11): 678-689. doi: 10.1038/nrm4074
WANG L, ZHU X, SUN X, et al. FoxO3 Regulates Hepatic Triglyceride Metabolism via Modulation of the Expression of Sterol Regulatory-Element Binding Protein 1c[J]. Lipids in Health and Disease, 2019, 18(1): 197. doi: 10.1186/s12944-019-1132-2
REN L Y, SUN D M, ZHOU X, et al. Chronic Treatment with the Modified Longdan Xiegan Tang Attenuates Olanzapine-Induced Fatty Liver in Rats by Regulating Hepatic de Novo Lipogenesis and Fatty Acid Beta-Oxidation-Associated Gene Expression Mediated by srebp-1c, ppar-alpha and ampk-alpha[J]. Journal of Ethnopharmacology, 2019, 232: 176-187. doi: 10.1016/j.jep.2018.12.034
LONGO N, FRIGENI M, PASQUALI M. Carnitine Transport and Fatty Acid Oxidation[J]. Biochimica et Biophysica Acta, 2016, 1863(10): 2422-2435. doi: 10.1016/j.bbamcr.2016.01.023
WANG W, BAI M R, JIANG T, et al. Clozapine-Induced Reduction of L-Carnitine Reabsorption via Inhibition/down-Regulation of Renal Carnitine/Organic Cation Transporter 2 Contributes to Liver Lipid Metabolic Disorder in Mice[J]. Toxicology and Applied Pharmacology, 2019, 363(15): 47-56.
OH K J, PARK J, LEE S Y, et al. Atypical Antipsychotic Drugs Perturb AMPK-Dependent Regulation of Hepatic Lipid Metabolism[J]. American Journal of Physiology Endocrinology and Metabolism, 2011, 300(4): E624-E632. doi: 10.1152/ajpendo.00502.2010
KERSTEN S, STIENSTRA R. The Role and Regulation of the Peroxisome Proliferator Activated Receptor Alpha in Human Liver[J]. Biochimie, 2017, 136: 75-84. doi: 10.1016/j.biochi.2016.12.019
WEN G P, RINGSEIS R, EDER K. Mouse OCTN2 is Directly Regulated by Peroxisome Proliferator-Activated Receptor α (PPARα) via a PPRE Located in the First Intron[J]. Biochemical Pharmacology, 2010, 79(5): 768-776. doi: 10.1016/j.bcp.2009.10.002
WEN G P, KVHNE H, RAUER C, et al. Mouse Γ-Butyrobetaine Dioxygenase is Regulated by Peroxisome Proliferator-Activated Receptor α through a PPRE Located in the Proximal Promoter[J]. Biochemical Pharmacology, 2011, 82(2): 175-183. doi: 10.1016/j.bcp.2011.04.006